UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 10.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 389,530 shares of the biotechnology company’s stock after selling 43,373 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.19% of BioCryst Pharmaceuticals worth $2,960,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BCRX. CWM LLC raised its stake in BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 3,772 shares during the last quarter. Signaturefd LLC increased its holdings in shares of BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,599 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth about $63,000. Finally, DRW Securities LLC purchased a new stake in BioCryst Pharmaceuticals in the second quarter valued at approximately $74,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BCRX. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Barclays boosted their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $7.53 on Friday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The firm has a market cap of $1.56 billion, a PE ratio of -12.34 and a beta of 1.79. The company has a 50-day moving average of $7.61 and a two-hundred day moving average of $7.39.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same period in the prior year, the firm earned ($0.19) earnings per share. The business’s revenue was up 35.1% compared to the same quarter last year. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.